tiprankstipranks
Advertisement
Advertisement

Rathbones Takes 7.74% Stake in Fusion Antibodies

Story Highlights
  • Fusion Antibodies is a Northern Ireland CRO providing end-to-end antibody discovery and engineering services.
  • Rathbones Investment Management has acquired a 7.74 percent equity stake in Fusion Antibodies, signaling institutional confidence.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Rathbones Takes 7.74% Stake in Fusion Antibodies

Claim 55% Off TipRanks

Fusion Antibodies Plc ( (GB:FAB) ) has issued an update.

Fusion Antibodies plc reported that Rathbones Investment Management Ltd, through Rathbones Nominees Limited, has built a holding of 9,679,837 ordinary shares in the company, equivalent to approximately 7.74% of its issued share capital. The increased stake by a well-known institutional investor signals a notable level of support for Fusion Antibodies’ strategy in the expanding antibody therapeutics and diagnostics market and may be interpreted by stakeholders as a vote of confidence in the company’s growth prospects and positioning within the sector.

The most recent analyst rating on (GB:FAB) stock is a Hold with a £13.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.

Spark’s Take on GB:FAB Stock

According to Spark, TipRanks’ AI Analyst, GB:FAB is a Neutral.

Fusion Antibodies Plc’s overall stock score is primarily impacted by its weak financial performance and concerning valuation. While there is some technical momentum, the negative P/E ratio and lack of profitability are significant risks. The absence of earnings call data and corporate events limits additional insights.

To see Spark’s full report on GB:FAB stock, click here.

More about Fusion Antibodies Plc

Fusion Antibodies plc is a Northern Ireland-based contract research organisation specialising in pre-clinical antibody discovery, engineering and expression services for human and veterinary therapeutics as well as diagnostic applications. The company provides an integrated end-to-end offering, including antigen design and expression, antibody discovery, characterisation, optimisation, humanisation via its proprietary CDRx platform, purification, sequencing and cell line development, and has worked on thousands of antibodies and over 290 humanisation projects for a global client base that includes major pharmaceutical companies in a rapidly growing antibody therapeutics market.

Average Trading Volume: 820,627

Technical Sentiment Signal: Buy

Current Market Cap: £18.13M

See more insights into FAB stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1